[iNOVA4Health Seminar] From bench to clinic, NextCell’s journey of evolution in cell therapy
Lindsay Davies
| When |
13 Mar, 2026
from
12:00 pm to 01:00 pm |
|---|---|
| Where | ITQB NOVA Auditorium |
| Contact Name | Margarida Serra |
| Contact Email | mserra@itqb.unl.pt |
| Add event to your calendar |
iCal
|
Title: From bench to clinic, NextCell’s journey of evolution in cell therapy
Speaker: Lindsay Davies
From: CSO of NextCellPharma; CEO of QVance
Abstract: Lindsay Davies is the current CSO of NextCell Pharma and CEO of new start-up QVance in Stockholm, Sweden. Dr. Davies has worked for over 20 years in the field of cell and gene therapy, first within academia as an Associate Professor at Karolinska Institutet, before starting her own advanced therapy consulting company in 2020 and later moving into industry working for NextCell.
NextCell Pharma is a clinical stage cell therapy company working with umbilical cord mesenchymal stromal cells for the treatment of type 1 diabetes and other autoimmune and inflammatory disorders. The company has demonstrated in Phase II clinical trials efficacy of their drug product in slowing the progression of type 1 diabetes in newly diagnosed individuals. Today Lindsay will discuss NextCell’s journey through product development and into late-stage clinical trials and the challenges that they have faced.
She will also outline how the company has evolved and tackled gaps in the market, including the launch of QVance, a quality control analytics company specific for advanced therapy developers inside of Europe.
